Selective DPP-4 inhibitors, including sitagliptin, are a new class of oral hypoglycemics approved for the treatment of type II diabetes because they avoid the inactivation of glucagon-like peptide 1 (GLP-1) [203]. Here, GCG is linked to type 2 diabetes mellitus.